Modality
Radioligand
MOA
BCMA ADC
Target
FcRn
Pathway
Neuroinflam
ADHD
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
Jun 2018
→ Feb 2031
Phase 2Current
NCT06646859
2,135 pts·ADHD
2019-11→2030-10·Recruiting
NCT05270176
470 pts·ADHD
2018-06→2031-02·Terminated
2,605 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2030-10-174.5y awayPh3 Readout· ADHD
2031-02-044.8y awayPh3 Readout· ADHD
Trial Timeline
Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P2/3
Termina…
P2/3
Recruit…
Catalysts
Ph3 Readout
2030-10-17 · 4.5y away
ADHD
Ph3 Readout
2031-02-04 · 4.8y away
ADHD
RecruitingTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06646859 | Phase 2/3 | ADHD | Recruiting | 2135 | SeizFreq |
| NCT05270176 | Phase 2/3 | ADHD | Terminated | 470 | UPDRS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Gelinaritide | AbbVie | Preclinical | FcRn | |
| AZN-3724 | AstraZeneca | Preclinical | PSMA | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| Talalemzoparlimab | Gilead Sciences | Phase 1 | FcRn | |
| Sovafutibatinib | Moderna | Approved | FcRn | |
| ITC-879 | Intra-Cellular | Approved | FcRn | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Sematenlimab | Samsung Biologics | Phase 3 | PI3Kα |